Dr. Miletello is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7777 Hennessy Blvd
Ste 6000
Baton Rouge, LA 70808Phone+1 225-757-0343Fax+1 225-757-8354
Education & Training
Louisiana State University School of MedicineFellowship, Hematology and Medical Oncology, 1983 - 1984- Louisiana State University School of MedicineResidency, Internal Medicine, 1981 - 1982
Ochsner Clinic FoundationResidency, Internal Medicine, 1981 - 1981- Louisiana State University School of Medicine in New OrleansClass of 1979
Certifications & Licensure
LA State Medical License 1980 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
- PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
- HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Start of enrollment: 2012 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 12 citationsLong-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2.Joseph I. Clark, Brendan Curti, Elizabeth J. Davis, Howard L. Kaufman, Asim Amin
Journal of Investigative Medicine. 2021-02-04 - 35 citationsOverall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM re...Mayer Fishman, Janice P. Dutcher, Joseph I. Clark, Ajjai Alva, Gerald P Miletello
Journal for Immunotherapy of Cancer. 2019-03-27 - 102 citationsTherapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibitionElizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna Pradyuman Patel
Journal for Immunotherapy of Cancer. 2019-02-18
Press Mentions
Unnecessary Medicare Advantage Denials: Harming Louisiana Patients, Crowding Our Emergency Departments, and Costing U.S. Providers BillionsSeptember 18th, 2024
Baton Rouge General Partners with Hematology Oncology Clinic to Expand Cancer ProgramSeptember 28th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
